Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-blind, Randomized, Parallel Group, Multicenter Study of the Safety and Tolerability of Betaseron 500 Mcg Subcutaneously Every Other Day and Betaseron 250 Mcg Subcutaneously Every Other Day for at Least 12 Weeks in Patients With RRMS

NCT00893217 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT00893217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00893217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-blind, Randomized, Parallel Group, Multicenter Study of the Safety and Tolerability of Betaseron 500 Mcg Subcutaneously Every Other Day and Betaseron 250 Mcg Subcutaneously Every Other Day for at Least 12 Weeks in Patients With RRMS
Lead sponsor
Bayer
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2002
Completion date
June 30, 2003
Enrollment
71 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis, relapsing-remitting